A Phase I/II Trial of HER2 Vaccine–Primed ...Treatment Refractory HER2–Overexpressing
 

This is a very hopeful news for Her2 Met patients!

A Phase I/II Trial of HER2 Vaccine–Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2–Overexpressing Breast Cancer

https://aacrjournals.org/clincancerr...dFrom=fulltext

Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets

https://aacrjournals.org/clincancerr...ved-from-Tumor